Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275400 · ClinicalTrials.gov registry record · Phase 3
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 986
- Enrollment target
NCT05275400 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 986 participants.
The verdict
NCT05275400, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 986 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin. The study consists of a 3-week screening/lead-in period, a 78-week treatment period and a 5-week safety follow-up period. The study will last up to 86 weeks.
Interventions
- DRUG Insulin Degludec
- DRUG Insulin Efsitora Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 986 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2024-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05275400
The ClinicalTrials.gov registry entry for NCT05275400 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 986 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Degludec is the first listed.
NCT05275400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05275400 about?
NCT05275400 is a clinical study titled "A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin". The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin. The study consists of a 3-week screening/lead-in period, a 78-week treatment period and a 5-week safet...
What is the current status of trial NCT05275400?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 986 participants. The study started on 2022-03-08. Estimated completion is 2024-05-15.
What interventions are being tested in trial NCT05275400?
The interventions under investigation include: Insulin Degludec (DRUG), Insulin Efsitora Alfa (DRUG).
Who is sponsoring clinical trial NCT05275400?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.